Joseph Ayoub, MD
Cardiovascular Disease · Council Bluffs, IANPI 1902888365
Payments from drug & device makers
Across 393 payments — averaging $49.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$14K
- E.r. Squibb & Sons, L.L.C.$624
- Abbott$592
- Novartis$528
- Johnson & Johnson$476
- Amgen$415
- plus $3K from 32 others
What the payments were for
- Travel & lodging$6,96636%
- Food & beverage$12,33364%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 166 | $14,077 |
| E.r. Squibb & Sons, L.L.C. | 43 | $624 |
| Abbott | 8 | $592 |
| Novartis | 41 | $528 |
| Johnson & Johnson | 31 | $476 |
| Amgen | 11 | $415 |
| Pfizer | 15 | $298 |
| AstraZeneca | 6 | $251 |
| Acist Medical Systems, Inc. | 5 | $229 |
| Amarin Pharma, Inc. | 4 | $156 |
| GSK | 2 | $153 |
| Boston Scientific | 8 | $143 |
| Gilead | 4 | $135 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Mylan Specialty L.p. | 1 | $111 |
| Actelion Pharmaceuticals US, Inc. | 7 | $102 |
| Scpharmaceuticals Inc. | 3 | $101 |
| Sanofi-aventis U.S. LLC | 5 | $87 |
| Nestle Healthcare Nutrition Inc. | 1 | $86 |
| Biohaven Pharmaceuticals, Inc. | 1 | $81 |
| Bridgebio Pharma, Inc. | 3 | $76 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $68 |
| Sanofi | 2 | $42 |
| Boehringer Ingelheim | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Merck | 2 | $31 |
| Cardiva Medical, Inc. | 1 | $31 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $29 |
| Abiomed | 1 | $28 |
| Atricure, Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
| Cardiovascular Systems Inc. | 1 | $17 |
| Opsens Inc. | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Convatec Inc. | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arctic Front$1,319
- ARCTIC FRONT ADVANCE$1,201
- Micra$1,115
- DIAMONDTEMP BIDIRECTIONAL ABLATION CATHETER$779
- CARDIOBLATE CRYOFLEX$743
- LINQ II$721
- COBALT DR MRI SURESCAN$293
- Claria MRI$161
- AURORA EV-ICD MRI SURESCAN$148
- Cobalt$144
- Evera$140
- Reveal LINQ$125
- Vascepa$125
- NEXLIZET$125
- NEXLETOL$125
- AIMOVIG$125
- EVENITY$125
- TRELEGY ELLIPTA$124
- Viva$123
- Quadra Assura CRT Defibrillator$118
How this compares
$19,309 in reported general payments places this provider in the 85th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,243 | $842,528 |
| XareltoRivaroxaban | 267 | $249,353 |
| EntrestoSacubitril/Valsartan | 162 | $137,061 |
| Repatha SureclickEvolocumab | 82 | $66,906 |
| MultaqDronedarone Hcl | 29 | $38,697 |
| VascepaIcosapent Ethyl | 46 | $26,372 |
| Praluent PenAlirocumab | 32 | $16,516 |
| JardianceEmpagliflozin | 16 | $11,744 |
| OzempicSemaglutide | 11 | $10,480 |
| Ranolazine ErRanolazine | 92 | $9,935 |
| CorlanorIvabradine Hcl | 15 | $9,200 |
| Amiodarone Hcl | 888 | $7,762 |
| Icosapent Ethyl | 16 | $6,086 |
| Metoprolol Succinate | 801 | $6,003 |
| Atorvastatin Calcium | 808 | $5,168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $298 | $842,5281,243 claims |
| Johnson & JohnsonXarelto | $476 | $249,353267 claims |
| NovartisEntresto | $528 | $137,061162 claims |
| Sanofi-aventis U.S. LLCMultaq | $87 | $38,69729 claims |
| Boehringer IngelheimJardiance | $36 | $11,74416 claims |
| Novo NordiskOzempic | $15 | $10,48011 claims |
| AmgenCorlanor | $415 | $9,20015 claims |
| AstraZenecaBrilinta | $251 | $4,58511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in Council Bluffs
- Terrence SlatteryCouncil Bluffs$4K
- Anand DeshmukhCouncil Bluffs$3K
- Thomas BrandtCouncil Bluffs$3K
- Troy HounshellWest Des Moines$1.4M
- Jennifer RobinsonIowa City$1.3M
- Lucas GrobenWest Des Moines$458K
- Enrico MartinWest Des Moines$440K
- Brian OlshanskyIowa City$219K
- Jason RasmussenAmes$175K
- Suvasini LakshmananIowa City$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.